Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9943530 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(3 years from now) | |
US8906410 | EIRGEN | Oral dosage form of 25-hydroxyvitamin D |
Feb, 2027
(3 years from now) | |
US10213442 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(3 years from now) | |
US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US8778373 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
US8361488 | EIRGEN | Methods and compositions for controlled release oral dosage of a vitamin D compound |
Jul, 2028
(5 years from now) | |
US8426391 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Aug, 2028
(5 years from now) | |
US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
28
United States
12
European Union
10
Korea, Republic of
10
Japan
9
Hong Kong
8
Denmark
8
Spain
8
Portugal
7
Poland
7
Slovenia
5
Canada
5
Hungary
5
Lithuania
4
China
3
Croatia
3
Cyprus
3
RS
2
Australia
2
EA
2
Israel
2
Singapore
2
Philippines
2
Norway
1
New Zealand
1
Peru
1
Saudi Arabia
1
Malaysia
1
Costa Rica
1
Chile
1
Ukraine
1
Mexico
1
Germany
1
Argentina
1
Brazil
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic